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Pemphigus vulgaris (PV) is a life-threatening autoimmune blister-
ing skin disease characterized by detachment of keratinocytes
(acantholysis). It has been proposed that PV IgG might trigger
signaling and that this process may lead to acantholysis. Indeed,
we recently identified a rapid and dose-dependent phosphoryla-
tion of p38 mitogen-activated protein kinase (p38MAPK) and heat
shock protein (HSP) 27 after binding of PV antibodies to cultured
keratinocytes. In human keratinocyte cultures, inhibitors of
p38MAPK prevented PV IgG-induced phosphorylation of HSP27
and, more importantly, prevented the early cytoskeletal changes
associated with loss of cell–cell adhesion. This study was under-
taken to (i) determine whether p38MAPK and HSP25, the murine
HSP27 homolog, were similarly phosphorylated in an in vivo model
of PV and (ii) investigate the potential therapeutic use of p38MAPK
inhibition to block blister formation in an animal model of PV. We
now report that p38MAPK inhibitors prevented PV blistering
disease in vivo. Targeting the end-organ by inhibiting keratinocyte
desmosome signaling may be effective for treating desmosome
autoimmune blistering disorders.
autoimmune  signaling
Pemphigus vulgaris (PV) is a life-threatening autoimmuneblistering disease where the autoimmune response targets
the epidermis and mucosal epithelia, resulting in f laccid
blisters and erosions. The loss of epithelial integrity disrupts
the skin barrier function, putting patients at risk for infection
as well as f luid and electrolyte imbalance. Before the intro-
duction of systemic corticosteroids, the disease was highly
lethal. Although the mortality has been reduced through the
use of steroids and potent immunosuppressive drugs, the
disease remains lethal, and patients often suffer from and may
succumb to the secondary effects of the medications used to
treat the disease.
In PV, IgG autoantibodies that bind to the surface of
epithelial cells are pathogenic. IgG purified from PV patient
sera causes blistering in mouse models (1, 2). In the PV IgG
passive transfer model, autoantibodies purified from patient
sera bind to keratinocyte desmoglein 3 (dsg3) (3–5) and induce
loss of cell–cell adhesion, reproducing the clinical and histo-
logical features of the human disease (1, 2). In both the human
disease and the PV mouse model, gentle friction of perilesional
skin causes sloughing of epidermal sheets (Nikolsky’s sign).
Although the model mimics aspects of the disease, the mo-
lecular mechanisms of blister formation remain unresolved. In
the passive transfer model, the epidermal cell–cell detachment
induced by PV autoantibodies is neither Fc- (6), complement-
(7), nor plasminogen activator-dependent (8). Thus, the PV
passive transfer mouse model represents an end-organ damage
model triggered by anti-dsg3 autoantibodies.
It has been proposed that PV IgG might trigger signaling and
that this process may lead to acantholysis (9–16). Indeed, we
recently identified a rapid and dose-dependent phosphoryla-
tion of p38 mitogen-activated protein kinase (p38MAPK) and
heat shock protein (HSP) 27 after binding of PV antibodies to
cultured keratinocytes (14). PV IgG-induced phosphorylation
of p38MAPK and HSP27 was followed by (i) remodeling of the
actin cytoskeleton and (ii) keratin intermediate filament re-
traction. In human keratinocyte cultures, inhibitors of
p38MAPK prevented PV IgG-induced phosphorylation of
HSP27 and, more importantly, prevented the early cytoskel-
etal changes associated with loss of cell–cell adhesion (14). We
suggested that the observed effects may be important to the
mechanism of PV IgG-induced acantholysis because HSP27
has been shown to regulate both actin (17–19) and interme-
diate filaments (20, 21). Furthermore, p38MAPK-mediated
phosphorylation of HSP27 had been shown to regulate the
cytoskeleton (22–24). Collectively, these observations sug-
gested that inhibition of this signaling pathway in epidermal
epithelia (Fig. 1) could be used to prevent end-organ damage
(e.g., blistering) caused by autoantibodies in PV.
If keratinocyte p38MAPK and HSP27 phosphorylation are
part of the acantholytic mechanism, then inhibiting them might
prevent PV IgG-induced blistering in an animal model of the
disease. This study was undertaken to (i) determine whether
p38MAPK and HSP25, the murine HSP27 homolog, were
similarly phosphorylated in an in vivo model of PV and (ii)
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Fig. 1. Model of the molecular mechanism of acantholysis in PV. Autoanti-
body binding to the desmosome cadherin dsg3 on the surface of epidermal
keratinocytes activates sequential phosphorylation of p38MAPK, MAPKAP
kinase 2, and HSP27, which is associated with keratin filament retraction, actin
cytoskeletal remodeling, and loss of cell–cell adhesion, leading to suprabasilar
acantholysis in the skin. Inhibition of keratinocyte p38MAPK blocks these
events in tissue culture and blister formation in vivo.











investigate the potential therapeutic use of p38MAPK inhibi-
tion to block blister formation in an animal model of PV.
To test whether p38MAPK inhibitors could block blister
formation in vivo, we have taken advantage of the PV mouse
model developed in our laboratories (1). In this model, the IgG
fraction from patients and control nonaffected normal individ-
uals is purified and passively transferred into neonatal mice (1,
25), reproducing the clinical and histological features of the
human disease. We now demonstrate that inhibitors of
p38MAPK prevent blister formation in this PV mouse model.
Results
Neonatal mice were injected intradermally (i.d.) with PV and
normal IgG (1.0 or 1.5 mgg body weight) as described (6). The
p38MAPK inhibitors were administered i.d. in two doses. One
of 6.25 g of SB202190 was given 2 h before the i.d. injection
of IgG. The second dose of the same amount of inhibitor was
mixed with PV or control IgG and injected i.d. Each animal
received a total dose of 12.5 g of inhibitor. After 18 h, the skin
of neonatal mice from the test and control groups was
examined clinically and histologically as described (1, 25).
Perilesional skin biopsies were examined by direct immuno-
f luorescence (IF) for the presence of PV IgG bound to the
epidermal epithelium. Serum samples were collected from the
test animals and analyzed for the presence of circulating
anti-dsg3 antibodies by ELISA by using the recombinant
human dsg3 ectodomain as described (26). Consistent with
previous reports, mice injected with PV IgG developed blisters
and a positive Nikolsky’s sign (Fig. 2 and Table 1). Histological
examination revealed suprabasilar acantholysis (Fig. 3 and
Table 2). In contrast, mice treated with the p38MAPK inhib-
itor SB202190 and pathogenic PV IgG failed to develop
blisters, clinically (Fig. 2 and Table 1) and histologically (Fig.
3 and Table 2). Direct IF of nonlesional skin from both PV IgG
and PV IgG plus SB202190 mouse skin demonstrated PV
antibodies bound to the epidermal keratinocyte cell surface,
indicating that the inhibitor did not prevent or alter the binding
of PV autoantibodies to the target organ (Fig. 4). Further-
more, analyses of serum samples showed a similar level of
anti-dsg3 autoantibodies in the circulation of both PV IgG-
treated and PV IgG plus SB202190-treated mice (Fig. 5).
These results indicate that the inhibitor did not prevent the
diffusion of IgG to the tissue target, i.e., epidermis, nor did
they inhibit systemic absorption of the injected IgG. This
observation provides further support that the inhibitor was
mediating its anti-acantholytic effects by targeting epidermal
keratinocytes.
We next examined the phosphorylation state of p38MAPK
and HSP25, the murine HSP27 homolog, because our previous
observations in human keratinocyte cell cultures demon-
strated that both proteins were phosphorylated when keratin-
ocyte cultures were exposed to PV IgG. Consistent with these
prior observations, skin extracts from PV IgG-treated mice
demonstrated increased phosphorylation of both p38MAPK
and HSP25 (Fig. 6). The same amount of total p38MAPK
immunoreactivity was present in skin extracts from control, PV
IgG, and PV IgG plus inhibitor-treated mice. In contrast,
increased phospho-p38MAPK immunoreactivity was observed
Fig. 2. Inhibiting p38MAPK prevents clinical blistering in PV passive transfer
mice. Neonatal C57BL6J mice were injected i.d. with either PV IgG (1.5 mg of
IgGg body weight) (Left) or PV IgG (1.5 mg of IgGg body weight) plus
SB202190 (Right). After 18 h, the skin of neonatal mice from the test and
control groups was examined clinically. PV IgG-treated mice have a positive
Nikolsky’s sign (white arrows), demonstrating loss of epithelial cell–cell ad-
hesion. In contrast, mice treated with the SB202190 and PV IgG have a
negative Nikoslky’s sign, indicating that epithelial adhesion remains intact.





PV IgG* 11 1
PV IgG  SB202190* 1 11
*Neonatal mice injected with PV IgG (1.5 mgg) or PV IgG plus SB202190 and
examined 18 h later for Nikolsky’s sign. A total of 24 mice per group were
injected. Eleven of 12 mice injected with PV IgG had a positive Nikoslky’s sign,
whereas only 1 of the 12 mice injected with PV IgG plus SB202190 had a
positive Nikolsky’s sign.
Fig. 3. Inhibiting p38MAPK prevents histologic blistering in PV passive
transfer mice. Skin biopsies of mice treated with control IgG (1 mg of IgGg
body weight) (Upper Left), PV IgG (1 mg of IgGg body weight) (Upper Right),
SB202190 (Lower Left), or SB202190 and then PV IgG (Lower Right) were fixed
in formalin and stained with hematoxylineosin. Suprabasilar acantholysis
leading to blister formation (*) is seen in PV IgG-treated mice but is blocked in
mice treated with SB202190 and PV IgG (PV IgG plus SB202190).





PV IgG* 11 1
PV IgG  SB202190* 1 11
*Neonatal mice were injected with PV IgG (1.0 mgg) and examined 18 h later
for presence of blister formation by microscopic examination of H&E-stained
skin biopsy sections. A total of 24 mice were injected. Eleven of 12 mice
injected with PV IgG developed suprabasilar acantholysis, whereas only 1 of
the 12 mice injected with PV IgG plus SB202190 demonstrated histological
evidence of blistering.
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in skin from PV IgG-treated mice; this PV IgG-activated
increase in p38MAPK phosphorylation was prevented by
treating mice with the p38MAPK inhibitor SB202190, sug-
gesting a role for p38MAPK autophosphorylation (27) in the
acantholytic process. When skin extracts were separated by 2D
electrophoresis and immunoblotted with antibodies to HSP25,
increased amounts of the most negatively charged HSP25
isoform were observed in PV IgG-treated mice (Fig. 6 C and
D). Increased phosphorylation of this HSP25 isoform was
inhibited in mice treated with PV IgG and the p38MAPK
inhibitor SB202190. Thus, both PV IgG-induced p38MAPK
and HSP25 phosphorylation were prevented when mice were
treated with SB202190. A second inhibitor of p38MAPK,
SB203580, also reduced blister formation in the PV mouse
model although the inactive analog SB202474 did not (Fig. 7).
Discussion
The cadherin family of cell adhesion molecules is important in
developmental biology (28), cell adhesion, neoplasia (29), and
human autoimmunity (30). Interestingly, in squamous epithe-
lium, the desmosomal cadherins dsg1 and dsg3 mediate cell
surface–cytoskeleton interactions that result in adhesive forces
that maintain the integrity of these tissues (31). Cell signaling
may play a critical role in these interactions. It has been known
that patients with pemphigus foliaceus (PF) and PV, two organ-
specific autoimmune diseases of squamous epithelium, manu-
facture anti-dsg1 and anti-dsg3 autoantibodies, which are patho-
genic by passive transfer experiments into recipient animals.
These autoantibodies bind epitopes located on the desmoglein
ectodomain and trigger cell signaling that is associated with
collapse of the cytoskeleton and cell detachment in vitro (14).
Exposure of human keratinocytes to pathogenic PV IgG
results in the phosphorylation of a number of intracellular
proteins. We observed increased p38MAPK and HSP27 phos-
phorylation in human keratinocyte tissue cultures exposed to PV
IgG. PV IgG-mediated phosphorylation of p38MAPK and
HSP27 was rapid, time- and dose-dependent events, occurring
within 15 min of addition of PV IgG (14). The rapid onset of
these events in tissue culture suggested that they may represent
some of the earliest events induced by PV IgG before loss of
cell–cell adhesion. These initial tissue culture studies suggested
a central role for p38MAPK in the mechanism of acantholysis;
however, in vivo testing in an animal model of PV was necessary
to demonstrate a role for p38MAPK in the acantholytic mech-
anism of the disease.
We observed that inhibitors of p38MAPK blocked blister
formation in vivo. Two different inhibitors of p38MAPK,
SB202190 and SB203580, inhibited PV IgG-induced blister
formation in the passive transfer mouse model although this
effect was more pronounced with SB202190. Importantly, the
inhibitor did not prevent systemic absorption of the PV IgG
nor did it prevent the binding of PV IgG to the keratinocyte
cell surface, indicating that the biologic effect of the inhibitor
was occurring downstream of antibody binding to keratinocyte
dsg3.
HSP27 and the related murine protein HSP25 function in
signal transduction where they may regulate the actin (17–19)
and intermediate filament (20, 21) cytoskeleton. Additionally,
p38MAPK-mediated phosphorylation of HSP27 modulates its
regulation of the cytoskeleton (22–24). Phosphorylation of
p38MAPK and HSP25 was observed in the skin of PV IgG-
treated mice, confirming that the same phosphorylation events
we had observed in tissue culture also occurred in vivo. Fur-
thermore, the PV IgG-induced phosphorylation of p38MAPK
and HSP25 was blocked in the skin of mice treated SB202190,
and this inhibition of phosphorylation correlated with the inhi-
bition of blister formation. The in vivo inhibition of PV IgG-
mediated p38MAPK phosphorylation by SB202190 suggests that
p38MAPK autophosphorylation (27) may be part of the acan-
tholytic process.
Taken together, our observations in the PV IgG passive
transfer model demonstrate that p38MAPK inhibitors can
prevent skin blistering by inhibiting PV IgG-activated signaling
in epidermal cells targeted by PV autoantibodies. In the
passive transfer mouse model, a single dose of pathogenic
human autoantibodies is administered to the test animal. In
the human disease, there is ongoing production of autoanti-
bodies. Thus, in PV patients, continuous dosing with inhibitor
will be required to block antibody-induced acantholysis. Al-
though the compounds used in this study are effective at
blocking keratinocyte p38MAPK and antibody-induced acan-
tholysis, they are not appropriate for clinical use in patients
suffering from pemphigus due to toxic side effects. Several
newer generation p38MAPK inhibitors are currently in clinical
trials for inf lammatory joint disease (32). The use of
p38MAPK inhibitors in PV may be a particularly attractive and
practical approach for treating the life-threatening autoim-
mune skin disease should these newer compounds prove safe
in people.
Methods
Materials. Rabbit polyclonal anti-HSP25 antibodies were from
StressGen (Victoria, BC, Canada), rabbit polyclonal anti-
p38MAPK antibodies were from Santa Cruz Biotechnology
(Santa Cruz, CA), monoclonal anti-phospho-p38MAPK anti-
bodies were from Cell Signaling Technology (Beverly, MA), and
Fig. 4. The inhibitor does not prevent the diffusion of IgG to the epidermis.
Perilesional skin biopsies from control (A), PV IgG-treated (B), and PV IgG plus
SB202190-treated (C) mice were examined for the presence of human anti-
dsg3 PV IgG by direct immunofluorescence by using a mouse anti-human
Cy-2-conjugated monoclonal antibody. A honeycomb pattern of staining in
the epidermis (arrows) is seen in both PV IgG- and PV IgG plus SB202190-
treated mice, demonstrating that the inhibitor does not prevent binding of PV
autoantibodies to the keratinocyte cell surface. Fig. 5. Anti-dsg3 IgG serum levels. The inhibitor does not prevent systemic
absorption of the injected IgG. Serum samples obtained from control, PV
IgG-treated, and PV IgG plus SB202190-treated mice were examined for the
presence of anti-dsg3 autoantibodies by using a dsg3 ectodomain-based
ELISA. P value is compared with control; n  3; SD is shown by error bars. P
values were calculated by using the Student t test.











polyclonal anti-lactate dehydrogenase V (LDH) antibodies were
from Cortex Biochem (San Leandro, CA). The p38MAPK
inhibitors SB202190 and SB203580 and the inactive analog
SB202474 were from Calbiochem (La Jolla, CA).
IgG Preparation. PV sera (mucocutaneous) have been described
(33). Data presented are from IgG purified from a single PV
patient whose serum was available in sufficient quantities to
carry out the described studies (the activity of this serum was
determined by indirect immunof luorescence on sectioned
monkey esophagus with a titer of 1:640). Two additional sera
were tested and demonstrated similar results. The PV IgG
were purified from PV patient sera by ammonium sulfate
precipitation followed by affinity chromatography on Protein
G (HiTrap; Amersham Pharmacia, Piscataway, NJ) as de-
scribed (14). IgG fractions were dialyzed against PBS and
sterile filtered. Purity was confirmed by SDSPAGE, and
activity was assayed by indirect IF and ELISA. Control IgG (no
activity by indirect IF) were prepared in parallel from normal
human sera.
Passive Transfer Mouse Model. Breeding pairs of C57BL6J mice
were purchased from The Jackson Laboratory (Bar Harbor,
ME) and maintained at the University of North Carolina
Division of Laboratory Animal Medicine Facility in accor-
dance with International Animal Care and Use Committee
protocols. Neonatal mice (24–36 h old with body weights
between 1.4 and 1.6 g) were used for passive transfer exper-
iments. Neonates were injected i.d. with a sterile solution of
either control IgG or PV IgG as described (1, 34, 35). For
direct clinical examination, mice were injected with PV or
control IgG at 1.5 mgg body weight in a total volume of 50 l
of PBS. This dose of PV IgG resulted in gross sloughing of the
skin. The skin of neonatal mice from the test and control
groups was examined 18 h after the injection of IgG for the
presence of Nikolsky’s sign, in which gentle friction of peri-
lesional skin causes sheet-like sloughing of the epidermis. A
second group of animals received a lower dose of PV IgG (1.0
mgg body weight in 50 l of PBS) to preserve the cutaneous
architecture lost by epithelial sloughing at the higher dose.
After clinical examination, the animals were killed, and skin
and serum specimens were obtained for routine histological
examination by using light microscopy (hematoxylineosin
staining) and direct IF assays to detect keratinocyte cell
surface-bound pemphigus IgG. Serum samples were assayed
Fig. 6. Inhibition of PV IgG-mediated p38MAPK and HSP27 phosphorylation in skin of PV IgG plus SB202190-treated mice. Neonatal C57BL6 WT mice were
injected i.d. with control IgG (CON; 1 mg of IgGg body weight), PV IgG (1 mg of IgGg body weight), or SB202190 and then PV IgG (PV IgG plus SB202190). Skin
biopsies were obtained after 18 h of treatment and extracted in IEF lysis buffer. (A) Samples were equally loaded on and separated by SDSPAGE, transferred
to PVDF, and immunoblotted with antibodies to p38MAPK, phospho-p38MAPK, or lactate dehydrogenase (LDH) as a loading control. Blots were developed by
enhanced chemiluminescence (ECL) reaction (Amersham Pharmacia). (B) Signal intensity from the ECL reaction for each band was quantified with a GeneGnome
scanner (Syngene Bio Imaging) by using GeneSnap software (n  3, SD shown by error bars). Total levels of p38MAPK are similar in control, PV IgG-treated, and
PV IgG plus SB202190-treated mice. Increased amounts of phospho-p38MAPK are present in PV IgG-treated mice (P value compared with control); this increase
is blocked in mice treated with SB202190 and PV IgG (no statistically significant difference for p38MAPK phosphorylation in PV IgG plus SB202190 compared with
controls, P  0.45, demonstrating in vivo block of p38MAPK phosphorylation). (C) Increased amounts of the most negatively charged HSP25 isoform (P2) were
observed in PV IgG-treated mice and blocked in mice treated with PV IgG plus SB202190. Skin extracts (30 g) were prepared and separated in the first dimension
by using 7 cm, pH 4–7 IPGphor strips (Amersham Pharmacia Biosciences) and in the second dimension by 10% SDSPAGE, followed by immunoblotting with
antibodies to murine HSP25 as described (14). (D) Signal intensity from the ECL reaction for each spot corresponding to the 2D gel HSP25 charge isoforms labeled
P0, P1, and P2 were quantified as above with a GeneGnome scanner and GeneSnap software (n  3; SD shown by error bars) and expressed as a percentage of
total HSP25 by using the formula Pn(P0  P1  P2), where Pn corresponds to the signal intensity for n  spot 0, 1, or 2 and P0  P1  P2 is the summed signal intensity
for all three HSP25 isoforms. An increase in the percentage of the most negatively charged HSP25 isoform, P2, is observed in skin extracts from PV IgG vs.
control-treated mice (*, P  0.04). This increase is blocked in mice pretreated with SB202190 (**, P  0.04 compared with PV IgG-treated mice). P values were
calculated by using the Student t test.
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for the presence of circulating human anti-dsg3 by IgG ELISA
against baculovirus-expressed ectodomains of human dsg3 as
described (26). Additional skin samples were harvested to
prepare protein extracts for SDSPAGE and 2D gel electro-
phoresis. After transfer to PVDF, membranes were probed by
immunoblot for proteins of interest. For in vivo inhibitor
studies, mice were preinjected with 6.25 g of SB202190 in 50
l i.d., and then reinjected i.d. with 6.25 g of SB202190 plus
PV IgG50 l (total of 12.5 g of SB202190 at 2 h). Various
doses of inhibitor were tested for their ability to block PV
IgG-induced acantholysis. The dose of 12.5 g of SB202190
was selected based on its ability to consistently block acan-
tholysis. Data representative of the dose response are pre-
sented in Fig. 8, which is published as supporting information
on the PNAS web site. No increased mortality was observed in
the inhibitor vs. control mice. As a control, a second group of
mice (n  3) was pretreated with the inactive analog SB202474
(total of 12.5 g of SB202470) (36) following the split dose
protocol used for SB202190. Additionally, a third group of
mice (n  3) was pretreated with the p38MAPK inhibitor
SB203580 (total of 25 g of SB202470) following the split dose
protocol used for SB202190. Blister formation was reduced
with SB203580; however, the effect was more pronounced with
SB202190.
2D Gel Electrophoresis. Extracts were prepared from skin biop-
sies by Dounce homogenization in IEF lysis buffer (8 M
urea4% CHAPS2.5 mM DTT40 mM Tris10 M pepsta-
tin100 M leupeptin10 M E-641 mM PMSF). Protein
concentration was by modified Bradford as described (37).
IPG buffer (pH 4–7; Amersham Pharmacia) was added to each
sample to a final concentration of 0.5% before isolelectric
focusing. Samples were separated in the first dimension by
using 7 cm, pH 4–7, linear IPGphor strips (Amersham Phar-
macia) and in the second dimension by 10% SDSPAGE. Gels
were transferred to PVDF membranes for immunoblot anal-
ysis. Western blots were developed by ECL reaction, and the
signal intensity was quantified by scanning chemiluminescence
on a GeneGnome scanner (Syngene Bio Imaging, Frederick,
MD) by using GeneSnap software. The signal intensity for
each HSP25 isoform was expressed as a percentage of total
HSP25 by using the formula Pn(P0  P1  P2), where n
corresponds to the signal intensity for spot 0, 1, or 2 and P0 
P1  P2 is the summed signal intensity for all three HSP25
isoforms. Statistical significance was determined by using the
Student t test.
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